22.692 articles found

OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS

GALLEY GUIDO, NORCROSS ROGER, POLARA ALESSANDRA.

· 2010-11-08

SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES

SNOW ALAN, WEIGELE MANFRED, LARSEN LESLEY, NGUYEN BETH, LAKE THOMAS, CASTILLO GERARDO, SANDERS VIRGINIA, WEAVERS REX T, LORIMER STEPHEN, LARSEN DAVID, COFFEN DAVID L, COFFEN CHARLOTTE.

· 2010-11-05

Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission.

Skodda S, Grönheit W, Schlegel U.

J Voice · 2010-11-04

DOI: 10.1016/j.jvoice.2010.04.007PMID: 21051196

The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.

Walker RW, Howells AR, Gray WK.

Parkinsonism Relat Disord · 2010-11-03

DOI: 10.1016/j.parkreldis.2010.10.005PMID: 21051272

Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.

Huang Q, Figueiredo-Pereira ME.

Apoptosis · 2010-11-01

DOI: 10.1007/s10495-010-0466-zPMID: 20131003

Deep brain stimulation therapy for Parkinson's disease using frameless stereotaxy: comparison with frame-based surgery.

Tai CH, Wu RM, Lin CH, Pan MK, Chen YF, Liu HM, Lu HH, Tsai CW, Tseng SH.

Eur J Neurol · 2010-11-01

DOI: 10.1111/j.1468-1331.2010.03035.xPMID: 20443976

Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility.

Gavaudan G, Magalon D, Cohen J, Lançon C, Léonetti G, Pélissier-Alicot AL.

J Forensic Sci · 2010-11-01

DOI: 10.1111/j.1556-4029.2010.01483.xPMID: 20579229

Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders.

White CM, Ji S, Cai H, Maudsley S, Martin B.

CNS Neurol Disord Drug Targets · 2010-11-01

DOI: 10.2174/187152710793361595PMID: 20632962

Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.

Albizu L, Moreno JL, González-Maeso J, Sealfon SC.

CNS Neurol Disord Drug Targets · 2010-11-01

DOI: 10.2174/187152710793361586PMID: 20632964

Prime time for G-protein-coupled receptor heteromers as therapeutic targets for CNS disorders: the dopamine D₁-D₃ receptor heteromer.

Ferré S, Lluis C, Lanciego JL, Franco R.

CNS Neurol Disord Drug Targets · 2010-11-01

DOI: 10.2174/187152710793361603PMID: 20632968

Transglutaminases as possible therapeutic targets in neurodegenerative diseases.

Martin A, De Vivo G, Ricotta M, Iannuzzi M, Gentile V.

Recent Pat CNS Drug Discov · 2010-11-01

DOI: 10.2174/157488910793362430PMID: 20636272

Pharmacological therapy of Parkinson's disease: current options and new avenues.

Simola N, Pinna A, Fenu S.

Recent Pat CNS Drug Discov · 2010-11-01

DOI: 10.2174/157488910793362421PMID: 20726838